Wednesday, September 18, 2019

OSE Immunotherapeutics Developing Tedopi® to Jump-Start Cytotoxic T-cell Response in Lung Cancer Fight

Tumor cells are usually recognized and destroyed through a complex mechanism of immune surveillance involving different immune cells (antigen presenting cells, macrophages, lymphocytes, proteins and mediators such as interleukins). Tumor cells can escape this surveillance mechanism by blocking immune cells’ activation. They can, for example, express...

Inivata Seeking to Develop Liquid Biopsy Tests to Detect Deadly Lung Cancers at a More Treatable Stage

Lung cancer is one of the most common types of cancer in the United States and, by far, the leading cause of cancer deaths. According to the National Cancer Institute (NCI), more than 234,000 Americans were diagnosed with lung cancer in 2018. An estimated 154,000...

The Peculiarity of Cancer Metastasis may be the Key to Controlling the Disease

Researchers at the National Institutes of Health (NIH) are taking a different approach to treating cancer, focusing on the disease’s deadly and perplexing process of metastasis, the migration of tumor cells beyond their original site. “There is no single drug approved for targeting (cancer) metastasis,”...

Expanding the Target Universe and the Therapeutic Opportunities of Small Molecules Through Covalency – Previously Thought Impossible

By Rich Soll (Senior Advisor, Strategic Initiatives, WuXi AppTec (@richsollwx). The current repertoire of tools suitable to interrogate biology and to translate this into therapeutic opportunities has been confined generally to small molecules and biologicals – although new approaches including gene editing and RNA-based technologies...

Towards the Realization of a Dream: Ending the Rare Disease Neurofibromatosa, a Conversation with the Children’s Tumor Foundation’s President Annette Bakker, Ph.D.

By Rich Soll (Senior Advisor, Strategic Initiatives, WuXi AppTec (@richsollwx). The mission of the Children’s Tumor Foundation (CTF) reads “drive research, expand knowledge, and advance care for the neurofibromatosis (NF) community.”  Sounds simple, yet despite disease complexity, this research-oriented foundation is making substantial progress towards...

SUBSCRIBE TO OUR NEWSLETTER

SPOTLIGHT

STAY CONNECTED

Twitter LinkedIn 

WUXI NEWS

WuXi AppTec Launches DNA Encoded Library (DEL) Service Package “DELight” to...

SHANGHAI; BOSTON, Sep. 3, 2019 - WuXi AppTec today announced its launch of DELight, a novel DNA Encoded Library (DEL) service package, providing...